termsTerm
BCG-unresponsive
The FDA's definition of early bladder cancer that has failed adequate BCG treatment, the population in which most new bladder drugs are first approved.
Persistent or recurrent CIS within 12 months of adequate BCG (at least 5 of 6 induction and 2 of 3 maintenance doses), or high-grade Ta/T1 recurrence within 6 months, or T1 high-grade at first evaluation after induction. Historically treated with radical cystectomy; now pembrolizumab, nadofaragene, N-803 + BCG, TAR-200, and (filing) cretostimogene offer bladder-sparing options with CR rates of 40-80%.
Clinical: what this kind of term is about · animated schematic, not to scale
Category
Clinical
cancers
1technologies
1drugs
5Phase 3Oncolytic adenovirus (intravesical)
Cretostimogene grenadenorepvec
ApprovedIntravesical drug-eluting device
Gemcitabine intravesical system (TAR-200) · Inlexzo
Not mapped hereLive bacterial immunotherapy (intravesical)
Intravesical BCG · TICE BCG
ApprovedNon-replicating adenoviral gene therapy (intravesical)
Nadofaragene firadenovec · Adstiladrin
ApprovedIL-15 superagonist (intravesical, with BCG)
Nogapendekin alfa inbakicept · Anktiva